These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 33305458)

  • 1. Theranostics Through the Synergistic Cooperation of Heterometallic Complexes.
    Redrado M; Fernández-Moreira V; Gimeno MC
    ChemMedChem; 2021 Mar; 16(6):932-941. PubMed ID: 33305458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs.
    Liu W; Gust R
    Chem Soc Rev; 2013 Jan; 42(2):755-73. PubMed ID: 23147001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insights into the Theranostic Activity of Nonoxido V
    Pattanayak PD; Banerjee A; Sahu G; Das S; Lima S; Akintola O; Buchholz A; Görls H; Plass W; Reuter H; Dinda R
    Inorg Chem; 2024 Oct; 63(41):19418-19438. PubMed ID: 39340532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multifunctional Au
    Zhang J; Zou H; Lei J; He B; He X; Sung HHY; Kwok RTK; Lam JWY; Zheng L; Tang BZ
    Angew Chem Int Ed Engl; 2020 Apr; 59(18):7097-7105. PubMed ID: 32049411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in ruthenium and platinum based supramolecular coordination complexes for antitumor therapy.
    Zhang X; Liu D; Lv F; Yu B; Shen Y; Cong H
    Colloids Surf B Biointerfaces; 2019 Oct; 182():110373. PubMed ID: 31376689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effects on Angiogenesis of Relevant Inorganic Chemotherapeutics.
    Marzo T; La Mendola D
    Curr Top Med Chem; 2021; 21(1):73-86. PubMed ID: 33243124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of a Novel Metallomics Tool to Probe the Fate of Metal-Based Anticancer Drugs in Blood Plasma: Potential, Challenges and Prospects.
    Sarpong-Kumankomah S; Gailer J
    Curr Top Med Chem; 2021; 21(1):48-58. PubMed ID: 32600232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Good Fashion is Evolution, Not Revolution" - Methods to Enhance Existing Anticancer Medicines, Primarily with the Use of Transition Metal.
    Guzowska M; Kalinowska M; Lewandowski W
    Anticancer Agents Med Chem; 2018; 18(4):476-487. PubMed ID: 29189181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metallodrugs: an approach against invasion and metastasis in cancer treatment.
    González-Ballesteros MM; Mejía C; Ruiz-Azuara L
    FEBS Open Bio; 2022 May; 12(5):880-899. PubMed ID: 35170871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pH-Sensitive Nanocarrier for Tumor Targeting : Delivery of Ruthenium Complex for Tumor Theranostic by pH-Sensitive Nanocapsule.
    Chen L; Fu C; Deng Y; Wu W; Fu A
    Pharm Res; 2016 Dec; 33(12):2989-2998. PubMed ID: 27590630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metallodrugs in cancer nanomedicine.
    Peña Q; Wang A; Zaremba O; Shi Y; Scheeren HW; Metselaar JM; Kiessling F; Pallares RM; Wuttke S; Lammers T
    Chem Soc Rev; 2022 Apr; 51(7):2544-2582. PubMed ID: 35262108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monomeric and dimeric coordinatively saturated and substitutionally inert Ru(ii) polypyridyl complexes as anticancer drug candidates.
    Notaro A; Gasser G
    Chem Soc Rev; 2017 Nov; 46(23):7317-7337. PubMed ID: 29027562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microenvironment-sensitive iridium(iii) complexes for disease theranostics.
    Lu N; Luo Y; Zhang Q; Zhang P
    Dalton Trans; 2020 Jul; 49(27):9182-9190. PubMed ID: 32542302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclometalated Ir(III) complexes as targeted theranostic anticancer therapeutics: combining HDAC inhibition with photodynamic therapy.
    Ye RR; Tan CP; He L; Chen MH; Ji LN; Mao ZW
    Chem Commun (Camb); 2014 Sep; 50(75):10945-8. PubMed ID: 25096019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biotinylated platinum(ii) metallacage towards targeted cancer theranostics.
    Wang X; Su Q; Zhang Z; Yang J; Zhang Y; Zhang M
    Chem Commun (Camb); 2020 Jul; 56(60):8460-8463. PubMed ID: 32583830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tracking antitumor metallodrugs: promising agents with the Ru(II)- and Fe(II)-cyclopentadienyl scaffolds.
    Morais TS; Valente A; Tomaz AI; Marques F; Garcia MH
    Future Med Chem; 2016 Apr; 8(5):527-44. PubMed ID: 27096164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Advances of Drugs for Cancer Theranostics.
    Feng LS
    Curr Top Med Chem; 2020; 20(16):1440. PubMed ID: 32705971
    [No Abstract]   [Full Text] [Related]  

  • 18. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.
    Ma L; Lin X; Li C; Xu Z; Chan CY; Tse MK; Shi P; Zhu G
    Inorg Chem; 2018 Mar; 57(5):2917-2924. PubMed ID: 29436828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ruthenium Complexes: An Emerging Ground to the Development of Metallopharmaceuticals for Cancer Therapy.
    Abid M; Shamsi F; Azam A
    Mini Rev Med Chem; 2016; 16(10):772-86. PubMed ID: 26423699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trackable Metallodrugs Combining Luminescent Re(I) and Bioactive Au(I) Fragments.
    Luengo A; Fernández-Moreira V; Marzo I; Gimeno MC
    Inorg Chem; 2017 Dec; 56(24):15159-15170. PubMed ID: 29172469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.